Urogen Pharma Ltd.
A biotech whose gel turns liquid to jelly at body heat, letting cancer drugs linger in the urinary tract for hours instead of minutes. Its FDA-approved treatments Jelmyto and Zusduri offer non-surgical options for rare bladder and kidney-tube cancers. Born in 2004 as Theracoat, it renamed itself UroGen in 2015 and won its first approval in 2020.
Granted 25.0K · Sold 104.1K
Granted 18.8K · Sold 9.0K
Granted 4.0K
Granted 4.5K · Sold 2.2K
Granted 2.0K
Granted 2.0K
Granted 2.0K
Granted 2.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Schoenberg MarkChief Medical Officer · 14 transactions | -60.1% | 59.1K | 25.0K | — | 104.1K |
| Smith Jason DrewGeneral Counsel · 8 transactions | +8% | 52.9K | 18.8K | — | 9.0K |
| Robinson James A. Jr.Director · 2 transactions | +50% | 6.0K | 4.0K | — | — |
| Degnan ChrisChief Financial Officer · 2 transactions | — | 2.3K | 4.5K | — | 2.2K |
| Butitta Cynthia MDirector · 1 transaction | — | 2.0K | 2.0K | — | — |
| Holden StuartDirector · 1 transaction | — | 2.0K | 2.0K | — | — |
| Wen LeanaDirector · 1 transaction | — | 2.0K | 2.0K | — | — |
| Wildman Daniel GeorgeDirector · 1 transaction | — | 2.0K | 2.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -115.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.